Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06590012
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-30
Brief Title:
Evaluating the Impact of 39Tertinat39 on Patients with Atherosclerosis-Related Cardiovascular Diseases
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Prospective Double-blind Comparative Randomized Placebo-controlled Multicenter Study Evaluating the Impact of Oral Administration of the Peroral Supplement 34Tertinat34 with Dosage of 330 Mgday for Patients with Cardiovascular Diseases the Cause of Which is Atherosclerosis on the Background of Standard Treatment
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TERACAD
Brief Summary:
The aim of this clinical trial is to evaluate whether the biologically active food supplement Tertinat can influence atherosclerosis progression in adults and improve the treatment outcomes of cardiovascular diseases The study will assess the frequency of fatal and clinically significant cardiovascular events monitored every 12 months following participants39 inclusion in the trial
Additionally the trial will evaluate Tertinats ability to prevent pro-atherogenic modification of lipoproteins and its impact on inflammatory activity To this end levels of desialylated low-density lipoproteins LDL and inflammatory markers in the blood will be monitored Tertinat administration will occur alongside the standard therapy prescribed to patients based on their existing medical conditions
Researchers will compare the effects of the Tertinat supplement to a placebo an identical-looking substance that does not contain the active supplement to determine if Tertinat is effective in reducing cardiovascular events
Participants will
Take either Tertinat or a placebo daily for a duration of 24 months Visit the clinic once a year for check-ups and testing
Additionally the trial will evaluate Tertinats ability to prevent pro-atherogenic modification of lipoproteins and its impact on inflammatory activity To this end levels of desialylated low-density lipoproteins LDL and inflammatory markers in the blood will be monitored Tertinat administration will occur alongside the standard therapy prescribed to patients based on their existing medical conditions
Researchers will compare the effects of the Tertinat supplement to a placebo an identical-looking substance that does not contain the active supplement to determine if Tertinat is effective in reducing cardiovascular events
Participants will
Take either Tertinat or a placebo daily for a duration of 24 months Visit the clinic once a year for check-ups and testing
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None